Sign Out
Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control.
For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studies, see Precautions, Interactions and Pharmacology: Pharmacodynamics under Actions.
